“Lebrikizumab-Treated Patients With Atopic Dermatitis Had No Increase in Treatment-Emergent Adverse Events of Facial, Head, and Neck Erythema Compared to Placebo”. SKIN The Journal of Cutaneous Medicine, vol. 7, no. 6, Nov. 2023, p. s272, https://doi.org/10.25251/skin.7.supp.272.